Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New anxiety drug candidate ITI-1284 enters Mid-Stage trial

NCT ID NCT06701903

First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 31 times

Summary

This study tests whether a daily tablet called ITI-1284, taken under the tongue, can help people with generalized anxiety disorder whose current treatments aren't working well enough. About 570 adults will receive either the drug or a placebo, and researchers will measure changes in anxiety symptoms over time. The trial is double-blind, meaning neither participants nor doctors know who gets the real drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cinical Site

    ACTIVE_NOT_RECRUITING

    Orlando, Florida, 32803, United States

  • Clinical Site

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • Clinical Site

    RECRUITING

    Little Rock, Arkansas, 72211, United States

  • Clinical Site

    RECRUITING

    Rogers, Arkansas, 72758, United States

  • Clinical Site

    RECRUITING

    Culver City, California, 90230, United States

  • Clinical Site

    RECRUITING

    Encino, California, 91316, United States

  • Clinical Site

    RECRUITING

    Los Angeles, California, 90025, United States

  • Clinical Site

    RECRUITING

    Oceanside, California, 92056, United States

  • Clinical Site

    RECRUITING

    Sherman Oaks, California, 91403, United States

  • Clinical Site

    ACTIVE_NOT_RECRUITING

    Upland, California, 91786, United States

  • Clinical Site

    RECRUITING

    Walnut Creek, California, 94596, United States

  • Clinical Site

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • Clinical Site

    ACTIVE_NOT_RECRUITING

    Gainesville, Florida, 32607, United States

  • Clinical Site

    RECRUITING

    Miami, Florida, 33176, United States

  • Clinical Site

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

  • Clinical Site

    NOT_YET_RECRUITING

    Tampa, Florida, 33613, United States

  • Clinical Site

    RECRUITING

    Decatur, Georgia, 30030, United States

  • Clinical Site

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

  • Clinical Site

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02131, United States

  • Clinical Site

    RECRUITING

    Flowood, Mississippi, 39232, United States

  • Clinical Site

    RECRUITING

    Brooklyn, New York, 11235, United States

  • Clinical Site

    ACTIVE_NOT_RECRUITING

    Buffalo, New York, 14215, United States

  • Clinical Site

    RECRUITING

    Staten Island, New York, 10314, United States

  • Clinical Site

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

  • Clinical Site

    RECRUITING

    Oklahoma City, Oklahoma, 73116, United States

  • Clinical Site

    RECRUITING

    Media, Pennsylvania, 19063, United States

  • Clinical Site

    NOT_YET_RECRUITING

    Dallas, Texas, 75231, United States

  • Clinical Site

    RECRUITING

    Dallas, Texas, 75243, United States

  • Clinical Site

    RECRUITING

    Bellevue, Washington, 98007, United States

  • Clinical Site

    RECRUITING

    Blagoevgrad, 2700, Bulgaria

  • Clinical Site

    RECRUITING

    Kardzhali, 6600, Bulgaria

  • Clinical Site

    RECRUITING

    Pleven, 5800, Bulgaria

  • Clinical Site

    RECRUITING

    Plovdiv, 4004, Bulgaria

  • Clinical Site

    RECRUITING

    Rousse, 7003, Bulgaria

  • Clinical Site

    RECRUITING

    Sofia, 1408, Bulgaria

  • Clinical Site

    RECRUITING

    Sofia, 1510, Bulgaria

  • Clinical Site

    RECRUITING

    Sofia, 1680, Bulgaria

  • Clinical Site

    RECRUITING

    Targovishte, 7700, Bulgaria

  • Clinical Site

    NOT_YET_RECRUITING

    Helsinki, 00100, Finland

  • Clinical Site

    NOT_YET_RECRUITING

    Kuopio, 70110, Finland

  • Clinical Site

    NOT_YET_RECRUITING

    Oulu, 90100, Finland

  • Clinical Site

    NOT_YET_RECRUITING

    Tampere, 33210, Finland

  • Clinical Site

    RECRUITING

    Bialystok, 15272, Poland

  • Clinical Site

    RECRUITING

    Bydgoszcz, 85-080, Poland

  • Clinical Site

    RECRUITING

    Gdansk, 80283, Poland

  • Clinical Site

    RECRUITING

    Leszno, 64100, Poland

  • Clinical Site

    RECRUITING

    Torun, 87100, Poland

  • Clinical Site

    RECRUITING

    Belgrade, 11000, Serbia

  • Clinical Site

    RECRUITING

    Kovin, 26220, Serbia

  • Clinical Site

    RECRUITING

    Kragujevac, 34000, Serbia

  • Clinical Site

    RECRUITING

    Niš, 18000, Serbia

  • Clinical Site

    RECRUITING

    Novi Kneževac, 23330, Serbia

  • Clinical Site

    RECRUITING

    Bratislava, 82101, Slovakia

  • Clinical Site

    RECRUITING

    Rimavská Sobota, 97901, Slovakia

  • Clinical Site

    RECRUITING

    Svidník, 08901, Slovakia

  • Clinical Site

    RECRUITING

    Vranov nad Topľou, 09301, Slovakia

  • Clinical Site_2

    RECRUITING

    Encino, California, 91316, United States

  • Clinical Site_2

    RECRUITING

    Belgrade, 11000, Serbia

  • Clinical Site_3

    RECRUITING

    Belgrade, 11000, Serbia

  • Clinical Site_4

    RECRUITING

    Belgrade, 11000, Serbia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ITI-1284 (a tablet taken under the tongue once daily)

What this could lead to

If successful, this could offer a new option for people with generalized anxiety disorder who don't get enough relief from existing treatments.

What could go wrong

This is an early Phase 2 trial, so results are uncertain. The drug may not work better than placebo, and side effects are still being studied.

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.